Loading...
Loading...
AVXL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 14.7M |
| Operating I/L | -14.7M |
| Other Income/Expense | 1.9M |
| Interest Income | 1.8M |
| Pretax | -12.8M |
| Income Tax Expense | -0.6M |
| Net Income/Loss | -12.2M |
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on developing drug candidates for the treatment of central nervous system diseases. Its lead drug candidate, ANAVEX 2-73, is in various stages of clinical trials for Alzheimer's disease, Rett syndrome, Parkinson's disease, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company also has ANAVEX 3-71 in Phase I clinical trial for frontotemporal dementia and other dementia indications, along with preclinical drug candidates for neurodegenerative diseases. Additionally, Anavex has preclinical drug candidates for the treatment of depression, stroke, Parkinson's, Alzheimer's diseases, neuropathic and visceral pain, and prostate and pancreatic cancer.
